AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2015
Jul 8, 2015
31580_dirs_2015-07-08_4117668b-0ad1-4f05-aee6-eb36d12d28ab.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2015-04-08
Reporting Person: Biller Scott (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-04-08 | Common stock | S | 5500 | $97.64 | Disposed | 39570 | Direct |
| 2015-05-07 | Common stock | S | 5500 | $96.32 | Disposed | 34070 | Direct |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $95.52 to $98.50. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price
F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $93.18 to $99.40. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.